Anton Grasch, MD
Family Medicine · Wenatchee, WANPI 1124469127
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Eli Lilly accounts for 79.0% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $18,938, more than ten times the $1,817 reported in 2019. Among family medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $391.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$25K
- Modernatx, Inc.$5K
- Sanofi Pasteur Inc.$2K
- Kvk-tech, Inc.$56
Across 284 payments — averaging $18,685 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.9M
- Modernatx, Inc.$1.4M
- Pfizer$1.2M
- GSK$394K
- Novartis$237K
- Merck$210K
What the payments were for
- Consulting fees$10,83834%
- Travel & lodging$9,54430%
- Food & beverage$11,33836%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 40 | $25,050 |
| Modernatx, Inc. | 23 | $4,798 |
| Sanofi Pasteur Inc. | 7 | $1,817 |
| Kvk-tech, Inc. | 11 | $56 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DISEASE STATE$1,802
How this compares
$31,720 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $26,764 |
| JardianceEmpagliflozin | 20 | $24,218 |
| EliquisApixaban | 25 | $17,843 |
| TrulicityDulaglutide | 11 | $12,807 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 64 | $11,774 |
| Tiotropium Bromide | 15 | $6,904 |
| Buprenorphine Hcl | 21 | $1,571 |
| Gabapentin | 70 | $1,545 |
| Atorvastatin Calcium | 151 | $1,493 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $1,040 |
| Losartan Potassium | 88 | $1,021 |
| Tamsulosin Hcl | 54 | $889 |
| Rosuvastatin Calcium | 45 | $819 |
| Metoprolol Succinate | 36 | $722 |
| Omeprazole | 62 | $615 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Wenatchee
- Andrew TothWenatchee$25K
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
- Marshall BrownPasco$70K
- Cynthia CoteMaple Valley$66K
- Greg LedgerwoodBrewster$66K
- Daniel RivasBurien$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.